Trials / Completed
CompletedNCT00866138
Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3
Phase II Study of AB1010 in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not Expressing FGFR3
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- AB Science · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2 study was designed to assess the safety and efficacy of masitinib (AB1010) in patients with relapsing/refractory t(4;14) Multiple Myeloma. Response and progression were assessed according to the Bladé revised IMWG criteria1 from lowest point.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | masitinib (AB1010) | masitinib 9 mg/kg/day per os |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-03-20
- Last updated
- 2019-12-03
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00866138. Inclusion in this directory is not an endorsement.